Dosimertinib is a selective, and orally bioactive and deuterated EGFR inhibitor under clinical trial for the treatment of NSCLC. Preclinical studies revealed that dosimertinib demonstrated robust in vivo antitumor efficacy and favorable PK profiles, but with lower toxicity than osimertinib.

纯度：≥98%

CAS：1421373-65-0 (unlabelled)